I saw an article touting the possible superiority of biobetters over biosimilars in Biopharma-reporter. In it, the author was suggesting that biobetters could establish a new bar that biosimilars could not meet and would therefore render them obsolete before they even got to market. To that I say, "Really?"
Does anyone out there, besides Roche, really believe that? I say "Wake up People!" Have you been looking at world economies recently? Have you noticed governments all over the world talking about problems of health care costs? Have you noticed these same governments becoming increasingly friendly to biosimilars? Have you noticed 3rd party payers increasingly bristling at high high high priced new drugs? If you haven't then where the hell have you been?
Biosimilars will make it to market -- all markets -- even in the US because they offer governments a way to push down drug costs on biologics. It's that simple. Get over it. All the arguments about how difficult it is to be biosimilar, automatic substitution, blah blah blah will be overwhelmed by economics. Third party payers simply will NOT pay for new drugs that don't show SUBSTANTIALLY increased benefits. That's all there is to say.
Posted by Bruce Lehr April 28th 2014